Review of Therapies using TiO2 Nanomaterials for Increased Anticancer Capability

Noé Rodríguez-Barajas1, Luis Miguel Anaya-Esparza1,2, Zuami Villagrán-de la Mora3

  • 1Laboratorio de Investigación en Materiales, Agua y Energía, Departamento de Ingeniería, Centro Universitario de los Altos, Universidad de Guadalajara, Tepatitlán de Morelos, Mexico.

Insights

Titanium dioxide nanoparticles show promise for cancer treatment when combined with therapies like photodynamic therapy. This combination enhances cancer cell killing, offering a potential new strategy for anticancer treatment.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Titanium dioxide (TiO2) is emerging as a novel agent for cancer therapy.
  • Its application is being explored across various activation-based treatment modalities.

Purpose of the Study:

  • To review the effects of TiO2 nanoparticles on cancer cell lines.
  • To examine the synergistic interactions between TiO2 and phototherapies for anticancer treatment.

Main Methods:

  • Literature review focusing on TiO2 nanoparticles.
  • Analysis of combination therapies including photodynamic therapy (PDT), photothermal therapy (PTT), sonodynamic therapy (SDT), and ultraviolet (UV) therapy.
  • Evaluation of cancer cell line responses.

Main Results:

  • TiO2 combined with PDT, PTT, SDT, or UV significantly enhanced cancer cell death.
  • The mechanism involves the increased formation of reactive oxygen species.
  • This combination therapy demonstrates a remarkable capacity for killing cancer cells.

Conclusions:

  • The combination of TiO2 nanoparticles with activation therapies presents a promising strategy for anticancer treatment.
  • Further research is needed to optimize parameters like TiO2 concentration and therapy conditions for safe and effective clinical application.

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
721
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
15.3K